5-year results: Orsiro - pushing the boundaries of safety performance3*
David E. Kandzari, MD, Atlanta, USA
David E. Kandzari, MD, Atlanta, USA
TLF – Target Lesion Failure; TV-MI - Target Vessel Myocardial Infarction; ST – Stent Thrombosis
Juan F. Iglesias, MD, Geneva, Switzerland
ACS – Acute Coronary Syndrome, STEMI – ST segment-Elevation Myocardial Infarction
Juan F. Iglesias, MD, Geneva, Switzerland
*Based on statistically significant lower TV-MI and late/very late definite/probable ST rates through 5 years for Orsiro DES vs Xience DP-EES in BIOFLOW-V. **Based on TLF rates from the BIOSTEMI trial. ∆ Posterior probability of superiority in STEMI in comparison to Xience at 24 months with respect to TLF, based on combined data set of BIOSTEMI and BIOSCIENCE STEMI groups.
1. In comparison to Xience Sierra, Resolute Onyx and Synergy for bench tests on pushability, trackability and crossability, BIOTRONIK data on file; 2. BIOTRONIK data on file, status January 2020; 3. Kandzari D et al. Ultrathin Bioresorbable Polymer Sirolimus-Eluting Stents versus Thin Durable Polymer Everolimus-Eluting Stents for Coronary Revascularization: Final 5-year Outcomes from the Randomized BIOFLOW V Trial, JACC, 2022: NCT02389946; 4. In comparison to Xience, based on BIOFLOW-V 5-year results; 5. Iglesias JF et al. Biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents in patients with ST-segment elevation myocardial infarction (BIOSTEMI): a single-blind, prospective, randomised superiority trial; Lancet, September, 2019.
Clinical data conducted with Orsiro, Orsiro Mission’s predecessor device can be used to illustrate Orsiro Mission clinical outcomes.
Orsiro and Orsiro Mission are trademarks or registered trademarks of the BIOTRONIK Group of Companies. All other trademarks are the property of their respective owners.
© 2022 BIOTRONIK AG – All rights reserved.
Specifications are subject to modification, revision and improvement.